IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$41.38 USD
+0.38 (0.93%)
Updated May 22, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
IDEAYA Biosciences, Inc. [IDYA]
Reports for Purchase
Showing records 121 - 140 ( 168 total )
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IND Submitted for MAT2A Development Candidate IDE397
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1 Study of IDE196 + Crizotinib in MUM
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Combination Study Begins as First Patient Dosed With IDE196 and Xalkori
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Robust Synthetic Lethality Pipeline Coming into Focus
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; IND Filing for the First Synthetic Lethality Program Drug, IDE397, Projected for December 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Update - Strong Cash Position and Robust Pipeline Execution
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Update - Strong Cash Position and Robust Pipeline Execution
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Partnership Strengthens Synthetic Lethality Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Key Takeaways from Our Talk Series
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Initiating OUTPERFORM with $21 PT; Lethal Precision Medicine
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDEAYA Clinical Collaboration With Pfizer Expanded to Include Combination of IDE196 With Xalkori
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Webinars to Discuss Near-Term Catalysts with Our Covered Companies
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; First Synthetic Lethality Candidate Could Reach the Clinic in 1H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E